youtube_live
Q2 2027 earnings • released • Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,665.00
arrow_downward
-5.30%(-205.00) 1D
ኖቬም 6, 3:30:00 ከሰዓት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,805
High
JP¥3,830
Low
JP¥3,665
Mkt. cap
170.58 ቢ
Avg. vol.
89.54 ሺ
Volume
122.40 ሺ
Dividend
3.27%
Quarterly dividend
JP¥30
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
13.58
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,805
High
JP¥3,830
Low
JP¥3,665
Mkt. cap
170.58 ቢ
Avg. vol.
89.54 ሺ
Volume
122.40 ሺ
Dividend
3.27%
Quarterly dividend
JP¥30
Ex-dividend date
29 ሴፕቴ 2026
P/E ratio
13.58
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
The Globe and Mail
·
ከ1 ሰዓት በፊት
Here's Why I'm Still Investing in the S&P 500, Even if a Bear Market Is Coming
Yahoo Finance
·
ከ1 ቀን በፊት
Tech stocks are now cheaper than the S&P 500 for the first time since 2017 — here's what history says comes next: Chart of the Day
Bloomberg
·
ከ1 ቀን በፊት
Wall Street Strategists Call Stock Rout a Fresh Reason to Buy
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp